Product Information

IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $2.8107 per EA under NDC 31722029730. Its NADAC has been published 43 times since Jan 28, 2026.

FDA first approved this application on Apr 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 400 MG TAB

IMATINIB MESYLATE
$2.8107per EA

Strength

400 mg/1

NDC

31722029730

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA212975

FDA Approved

4/14/2025

TE Code

AB

On Market Since

4/14/2025

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 43 times since Jan 28, 2026, and over the history we have for it it has declined 11.8%. The table below summarizes its recorded NADAC range and movement.

Current price$2.8107 per EA
All-time high$3.2150 (Mar 11, 2026)
All-time low$2.6771 (Sep 23, 2026)
52-week high$3.2150
52-week low$2.6771
Median price$2.9484
Average price$2.9690
Largest weekly change-6.9% (Sep 23, 2026)
Weeks tracked43
Tracking sinceJan 28, 2026

Price History

1W

+4.8%

1M

+5.0%

3M

-2.3%

6M

-6.8%

1Y

N/A

3Y

N/A

5Y

N/A

All

-11.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the IMATINIB MESYLATE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Camber Pharmaceuticals Inc., is $2.8107 per EA (NDC 31722029730), effective Nov 18, 2026.

How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 11.8%. It has been tracked across 43 weekly CMS publications since Jan 28, 2026.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?

Since Jan 28, 2026, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $2.6771 (Sep 23, 2026) to a high of $3.2150 (Mar 11, 2026), with a median of $2.9484 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?

No other NADAC-published product currently shares the active ingredient and strength of IMATINIB MESYLATE 400 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures IMATINIB MESYLATE 400 MG TAB?

IMATINIB MESYLATE 400 MG TAB (NDC 31722029730) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.